A clinical trial for the safety and immunogenicity of a DNA-based immunotherapy in men with biochemically (PSA) relapsed prostate cancer.
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Neal D. Shore, Elisabeth I. Heath, Luke T. Nordquist, Heather H. Cheng, Kamalnayan Bhatt, Nicholas Carroll, Kimberly Kraynyak, Jessica Lee, Jan Van Tornout, Brian Sacchetta, Scott T. Tagawa, Rahul Atul Parikh, Ronald F. Tutrone, Jorge A. Garcia, Young E. Whang, Jianqing Lin, William Kevin Kelly, Ildiko Csiki, Mark L. Bagarazzi
Institutions: Carolina Urologic Research Center, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Urology Cancer Center and GU Research Network, University of Washington, Inovio Pharmaceuticals (United States), Weill Cornell Medicine, University of Pittsburgh Medical Center, Chesapeake Urology Associates, Cleveland Clinic, University of North Carolina at Chapel Hill, Thomas Jefferson University, Sidney Kimmel Cancer Center, GlaxoSmithKline (United States)
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2598766631